Table 2 Design of registered trials
From: An evidence mapping and analysis of registered COVID-19 clinical trials in China
Number | Percentage | |
|---|---|---|
Trial phase | ||
Pilot study | 77 | 35.0 |
Phase 1 | 2 | 0.9 |
Phase 1/phase 2 | 3 | 1.4 |
Phase 2 | 5 | 2.3 |
Phase 2/phase 3 | 6 | 2.7 |
Phase 3 | 6 | 2.7 |
Phase 4 | 42 | 19.1 |
NP | 79 | 35.9 |
Number of arms | ||
0 | 2 | 0.9 |
1 | 49 | 22.3 |
2 | 107 | 48.6 |
3 | 25 | 11.4 |
4 | 10 | 4.4 |
5 | 5 | 2.3 |
6 | 1 | 0.5 |
8 | 1 | 0.5 |
NP | 20 | 9.1 |
Study design type | ||
Parallel design | 151 | 68.6 |
Factorial design | 17 | 7.7 |
NP | 52 | 23.6 |
Randomization | ||
Randomized | 122 | 55.5 |
Computer software | 68 | 55.7 |
Phone/WeChat | 1 | 0.8 |
NP | 53 | 43.4 |
Non-randomized | 73 | 33.2 |
NP | 25 | 11.4 |
Masking (blinding) | ||
Blinding | 23 | 10.5 |
Participant | 5 | 21.7 |
Investigator | 1 | 4.3 |
Investigator, outcomes assessor | 1 | 4.3 |
Participant, care provider, outcomes assessor | 1 | 4.3 |
Participant, care-provider, investigator, outcomes assessor | 4 | 17.4 |
NP | 11 | 47.8 |
Non-blinding | 67 | 30.5 |
NP | 130 | 59.0 |
Total sample size | ||
0–100 | 112 | 50.9 |
101–200 | 44 | 20.0 |
201–300 | 17 | 7.8 |
> 300 | 47 | 21.3 |
Severity of illness | ||
Mild | 2 | 0.9 |
Mild/common | 14 | 6.4 |
Mild/severe | 2 | 0.9 |
Mild/common/severe | 8 | 3.6 |
Mild/common/critical | 1 | 0.5 |
Common | 27 | 12.3 |
Common/severe | 6 | 2.7 |
Common/severe/critical | 3 | 1.4 |
Severe | 24 | 10.9 |
Severe/critical | 7 | 3.2 |
Critical | 6 | 2.7 |
NP | 120 | 54.5 |
The number of major outcome | ||
One | 104 | 47.2 |
Two | 37 | 16.8 |
Three | 31 | 14.1 |
More than three | 47 | 21.4 |
NP | 1 | 0.5 |
Control intervention type | ||
Positive drug | 14 | 6.4 |
Positive drug and conventional therapy | 3 | 1.4 |
TCM | 3 | 1.4 |
TCM and positive drug | 1 | 0.5 |
Placebo | 19 | 8.6 |
No treatment | 6 | 2.7 |
Conventional therapy | 89 | 40.5 |
NP | 85 | 38.6 |
Intervention type of experimental group | ||
Antiviral drug | 37 | 16.8 |
Biologicals | 22 | 10.0 |
Hormone drug | 7 | 3.2 |
Compound Chinese herbal medicine | 24 | 10.9 |
Traditional Chinese Medicine injection | 5 | 2.3 |
TCM and conventional western medicine | 26 | 11.8 |
TCM and antiviral drug | 1 | 0.5 |
Biologicals and conventional treatment | 10 | 4.5 |
Antiviral drug and hormone drug | 2 | 0.9 |
Antiviral drug and biologicals | 3 | 1.4 |
Antiviral drug and conventional treatment | 3 | 1.4 |
Antiviral drug and biologicals and hormone drug | 1 | 0.5 |
Antiallergic and conventional treatment | 1 | 0.5 |
Anti-inflammatory drug | 2 | 0.9 |
Vitamin C | 2 | 0.9 |
Sedative | 2 | 0.9 |
Drug to regulate intestinal flora and conventional treatment | 1 | 0.5 |
Daoyin + conventional treatment | 1 | 0.5 |
Acupoint stimulation and qigong and conventional treatment | 1 | 0.5 |
TCM and moxibustion | 1 | 0.5 |
NP | 68 | 30.9 |